Diabetic macular edema (DME) is an eye complication related to diabetes, primarily affecting the macula region of the eye.

TAR-200 treatment alone achieves over 80% total remission in high-risk patients with non-muscle-invasive bladder cancer.

May 7th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

Guangzhou Bio-gene Technologies has launched the first phase of clinical trials for its CAR-T cell therapy BG1805, which targets CLL-1.

4.29-5.5 Global Drug R&D Progress & Pharmaceutical Transaction Trends.

selectION, Inc. has shared encouraging outcomes from its initial human Phase 1b study concerning its primary drug, si-544, targeted at individuals with atopic dermatitis.

This paper reported an innovative computational approach that successfully achieved the design and prediction of macrocyclic oligoamides composed of alpha, beta, gamma, and other non-natural amino acid backbone chemical structures.

AriBio Granted EMA Approval for Phase 3 Trials of AR1001 in Alzheimer’s Treatment (POLARIS-AD).

A clinical trial default approval is a system where applicants can proceed with drug trials as planned if the review agency does not reject or question the submission within a set period.

Ractigen Therapeutics has received FDA clearance for RAG-01, a pioneering saRNA treatment for NMIBC that does not respond to BCG.

April 30th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

U.S. FDA Sanctions Single-Dose Gene Treatment BEQVEZ™ (fidanacogene elaparvovec-dzkt) by Pfizer for Adult Hemophilia B Patients.